NCT04893941 - Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 21, 2020

Primary Completion Date

January 22, 2021

Study Completion Date

January 22, 2021

Conditions

Moderate-to-severe Atopic Dermatitis

Interventions

DRUG

CM310

IL-4Rα monoclonal antibody

DRUG

Placebo

Trial Locations (7)

Second Xiangya Hospital of Central South University, Changsha

Wuxi Second Hospital, Wuxi

West China Hospital of Sichuan University, Chengdu

Hangzhou First People's Hospital, Hangzhou

Peking University People's Hospital, Beijing

Peking University Third Hospital, Beijing

Shanghai Skin Disease Hospital, Shanghai